Federal appeals court heavily questions FDA, Danco lawyers in abortion drug case
The fate of the abortion drug mifepristone is still up in the air in the US after three federal appeals court judges heavily questioned the government and Danco Laboratories over whether the FDA followed the proper process when it loosened access to the drug.
Mifepristone was first approved by the FDA in 2000, and the regulator made a number of changes in 2016 that broadened access to the progesterone blocker, including allowing it to be shipped in the mail and prescribed by a wider range of healthcare professionals, not just physicians.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters